Jeff Bezos has invested in the cellular rejuvenation startup Altos Labs, while Google’s Calico Labs is leading aging research by integrating AI with molecular biology. Consumer-facing industries are also entering the space: L’Oréal is collaborating with biotechnology companies to develop skincare targeting biological aging, and Nestlé is reportedly exploring nutritional solutions for longevity.
CRISPR Therapeutics is often regarded as a leading player in longevity science, prompting a review of its pipeline and related patents. Its approved therapy, CASGEVY, is indicated for sickle cell disease, while clinical-stage programs such as CTX310 (targeting ANGPTL3) are primarily focused on lipid metabolism disorders and the modulation of cardiovascular risk factors.
These diseases are not designed to directly target aging itself or to extend lifespan. Therefore, in a strict sense, their relevance to longevity science at the level of specific indications remains limited.
However, the fact that gene-editing therapeutics have successfully overcome clinical, regulatory, and manufacturing barriers to achieve commercialization is highly significant, as it demonstrates a platform capability that can be extended to aging-related mechanisms—such as chronic inflammation, metabolic risk factors, and functional decline of tissues. That is, the current connection to longevity science stems from its technological and industrial potential for expansion, rather than any direct clinical indications
Companies developing gene therapies that directly target cellular reprogramming:
1) Life Biosciences
- What does it do?
The company is developing OSK (Oct4, Sox2, Klf4)-based gene therapies that partially reverse epigenetic information in adult tissues (partial reprogramming). It is evaluating applications in ophthalmology, as well as systemic delivery of OSK using AAV vectors.
- Why is it attracting attention?
Proof-of-concept (PoC) studies demonstrating vision restoration in animal models—conducted by Harvard and Mass Eye and Ear—have received significant attention in both academia and mainstream media. As a company that has licensed Harvard’s underlying technology, Life Biosciences is widely regarded as a leading player in clinical translation.
- Representative patent (example)
- WO 2020/069373 A1: Covers compositions and methods for inducing age reversal and tissue regeneration by expressing OSK (OCT4, SOX2, and KLF4) via vectors such as AAV, including specific vector configurations (with corresponding family patents such as US 12,274,733 B2).
Simultaneous modulation of multiple aging pathways through a single combination gene therapy.
2) Rejuvenate Bio
- What does it do?
The company employs liver-targeted AAV vectors to enable single or combinatorial expression of genes such as FGF21 (metabolic regulation), sTGFβR2 (anti-fibrotic and anti-inflammatory), and α-Klotho (a longevity-associated factor), thereby simultaneously suppressing multiple disease pathways associated with aging (e.g., RJB-01/02). Preclinical studies in dogs and rodents have demonstrated multi-system improvements, including effects on body weight, metabolism, cardiac function, and renal function.
- Why is it attracting attention?
Rejuvenate Bio’s approach is based on a combination AAV strategy that aims to simultaneously target multiple aging pathways with a single gene therapy. It leverages liver-directed AAV vectors to achieve long-term expression of secreted therapeutic proteins. [PMC+2DAIC+2]
- Representative patent (example)
US 12,281,154 B2 (U.S. granted; published as US 2019/0345224 A1) — Gene therapy methods for age-related diseases and conditions
Claim 1 (summary): methods for treating conditions such as obesity, diabetes, heart failure, and renal failure by co-delivering sTGFβR2 and FGF21 either within a single viral vector or via a combination of separate vectors (i.e., a combination AAV configuration).
Also encompasses compositions and methods for single or multiple gene expression using viral vectors such as AAV to prevent or treat age-related diseases (including combinations of FGF21, Klotho, sTGFβR2, etc.), including multi-gene and combinatorial formulations. (Harvard-origin technology, commercialized via a licensed spin-out.)
Longevity science has evolved beyond the narrow scope of “aging research” into a convergent industry encompassing advanced biotechnologies such as gene therapy, cellular reprogramming, and AI-driven modulation of molecular aging. Approaches including CRISPR-based therapeutics, epigenetic reprogramming, and multi-gene combinatorial AAV therapies—while distinct in methodology—share a common objective: to enhance the body’s fundamental resilience and extend lifespan. Although still at an early stage, this field holds exponential innovation potential as clinical validity and technological safety continue to be established.
By Yeonsoo Park
Patent Attorney, BLT Patent & law Firm: www.en.blt.kr
#LongevityScience #HealthyLifespan #AgingBiology #CellularRejuvenation #GeneEditingTherapeutics #EpigeneticReprogramming #AAVVectors #GeneTherapyInnovation #BiotechIndustry #AIandBiology #MolecularAging #TranslationalMedicine #CRISPRTherapeutics #PatentLandscape #IPStrategy #LifeSciences #RegenerativeBiology #Biopharma #DeepTech #BLT
Jeff Bezos has invested in the cellular rejuvenation startup Altos Labs, while Google’s Calico Labs is leading aging research by integrating AI with molecular biology. Consumer-facing industries are also entering the space: L’Oréal is collaborating with biotechnology companies to develop skincare targeting biological aging, and Nestlé is reportedly exploring nutritional solutions for longevity.
CRISPR Therapeutics is often regarded as a leading player in longevity science, prompting a review of its pipeline and related patents. Its approved therapy, CASGEVY, is indicated for sickle cell disease, while clinical-stage programs such as CTX310 (targeting ANGPTL3) are primarily focused on lipid metabolism disorders and the modulation of cardiovascular risk factors.
These diseases are not designed to directly target aging itself or to extend lifespan. Therefore, in a strict sense, their relevance to longevity science at the level of specific indications remains limited.
However, the fact that gene-editing therapeutics have successfully overcome clinical, regulatory, and manufacturing barriers to achieve commercialization is highly significant, as it demonstrates a platform capability that can be extended to aging-related mechanisms—such as chronic inflammation, metabolic risk factors, and functional decline of tissues. That is, the current connection to longevity science stems from its technological and industrial potential for expansion, rather than any direct clinical indications
Companies developing gene therapies that directly target cellular reprogramming:
1) Life Biosciences
The company is developing OSK (Oct4, Sox2, Klf4)-based gene therapies that partially reverse epigenetic information in adult tissues (partial reprogramming). It is evaluating applications in ophthalmology, as well as systemic delivery of OSK using AAV vectors.
Proof-of-concept (PoC) studies demonstrating vision restoration in animal models—conducted by Harvard and Mass Eye and Ear—have received significant attention in both academia and mainstream media. As a company that has licensed Harvard’s underlying technology, Life Biosciences is widely regarded as a leading player in clinical translation.
Simultaneous modulation of multiple aging pathways through a single combination gene therapy.
2) Rejuvenate Bio
The company employs liver-targeted AAV vectors to enable single or combinatorial expression of genes such as FGF21 (metabolic regulation), sTGFβR2 (anti-fibrotic and anti-inflammatory), and α-Klotho (a longevity-associated factor), thereby simultaneously suppressing multiple disease pathways associated with aging (e.g., RJB-01/02). Preclinical studies in dogs and rodents have demonstrated multi-system improvements, including effects on body weight, metabolism, cardiac function, and renal function.
Rejuvenate Bio’s approach is based on a combination AAV strategy that aims to simultaneously target multiple aging pathways with a single gene therapy. It leverages liver-directed AAV vectors to achieve long-term expression of secreted therapeutic proteins. [PMC+2DAIC+2]
US 12,281,154 B2 (U.S. granted; published as US 2019/0345224 A1) — Gene therapy methods for age-related diseases and conditions
Claim 1 (summary): methods for treating conditions such as obesity, diabetes, heart failure, and renal failure by co-delivering sTGFβR2 and FGF21 either within a single viral vector or via a combination of separate vectors (i.e., a combination AAV configuration).
Also encompasses compositions and methods for single or multiple gene expression using viral vectors such as AAV to prevent or treat age-related diseases (including combinations of FGF21, Klotho, sTGFβR2, etc.), including multi-gene and combinatorial formulations. (Harvard-origin technology, commercialized via a licensed spin-out.)
Longevity science has evolved beyond the narrow scope of “aging research” into a convergent industry encompassing advanced biotechnologies such as gene therapy, cellular reprogramming, and AI-driven modulation of molecular aging. Approaches including CRISPR-based therapeutics, epigenetic reprogramming, and multi-gene combinatorial AAV therapies—while distinct in methodology—share a common objective: to enhance the body’s fundamental resilience and extend lifespan. Although still at an early stage, this field holds exponential innovation potential as clinical validity and technological safety continue to be established.
By Yeonsoo Park
Patent Attorney, BLT Patent & law Firm: www.en.blt.kr
#LongevityScience #HealthyLifespan #AgingBiology #CellularRejuvenation #GeneEditingTherapeutics #EpigeneticReprogramming #AAVVectors #GeneTherapyInnovation #BiotechIndustry #AIandBiology #MolecularAging #TranslationalMedicine #CRISPRTherapeutics #PatentLandscape #IPStrategy #LifeSciences #RegenerativeBiology #Biopharma #DeepTech #BLT